Guidelines for Prevention and Treatment of Chronic Hepatitis B

Guiqiang Wang, Zhongping Duan, Guiqiang Wang, Zhongping Duan

Abstract

To achieve the goal of the World Health Organization to eliminate viral hepatitis as a major public health threat by 2030, the Chinese Society of Infectious Diseases and the Chinese Society of Hepatology convened an expert panel in 2019 to update the guidelines for the prevention and treatment of chronic hepatitis B (CHB). The current guidelines cover recent advances in basic, clinical, and preventive studies of CHB infection and consider the actual situation in China. These guidelines are intended to provide support for the prevention, diagnosis, and treatment of CHB.

Keywords: Chronic; Guidelines; Hepatitis B; Prevention; Treatment.

Conflict of interest statement

The authors have no conflict of interests related to this publication.

© 2021 Authors.

Figures

Fig. 1. Flow chart of antiviral therapy…
Fig. 1. Flow chart of antiviral therapy for patients with chronic HBV infection.
(a) Follow-up tests: virological test, liver biochemical test, AFP test, PIVKA-II test, abdominal ultrasound, and liver stiffness measurement. (b) HBV-related extrahepatic manifestations: glomerulonephritis and vasculitis. (c) Follow-up criteria for patients with HBV-related decompensated cirrhosis during NA treatment: perform a routine blood test, liver biochemical test, renal function test, virological test, and test for blood ammonia, AFP, and PIVKA-II, and abdominal ultrasound every 3 months. If necessary, perform enhanced CT or MRI. (d) Other causes of ALT elevation: infection by other pathogens, history of drug or poison use, history of alcohol use, lipid metabolism disorders, autoimmune disorders, liver congestion or vascular diseases, inherited metabolic liver disease, systemic diseases. (e) NAs-ETV, TDF, TAF. HbsAg, hepatitis B surface antigen; HBV, hepatitis B virus; ALT, alanine aminotransferase; HCC, hepatocellular carcinoma; NAs, nucleos(t)ide analogs; peg-IFN-α, pegylated interferon-α.

References

    1. WHO. Global hepatitis report 2017. Available from:
    1. Cui F, Shen L, Li L, Wang H, Wang F, Bi S, et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China. Emerg Infect Dis. 2017;23(5):765–772. doi: 10.3201/eid2305.161477.
    1. Liu J, Liang W, Jing W, Liu M. Countdown to 2030: eliminating hepatitis B disease, China. Bull World Health Organ. 2019;97(3):230–238. doi: 10.2471/blt.18.219469.
    1. Xu Y, Liu H, Wang Y, Hao R, Li Z, Song H. The next step in controlling HBV in China. BMJ. 2013;347:f4503. doi: 10.1136/bmj.f4503.
    1. Lu Y, Zhu FC, Liu JX, Zhai XJ, Chang ZJ, Yan L, et al. The maternal viral threshold for antiviral prophylaxis of perinatal hepatitis B virus transmission in settings with limited resources: a large prospective cohort study in China. Vaccine. 2017;35(48):6627–6633. doi: 10.1016/j.vaccine.2017.10.032.
    1. Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599. doi: 10.1002/hep.29800.
    1. Schillie S, Vellozzi C, Reingold A, Harris A, Haber P, Ward JW, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep. 2018;67(1):1–31. doi: 10.15585/mmwr.rr6701a1.
    1. WHO. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection 2015. Available from:
    1. Action plan for the prevention and treatment of viral hepatitis in China (2017-2020) Chin J Viral Dis. 2018;8(01):1–5. doi: 10.16505/j.2095-0136.2018.0001.
    1. World Health Organization Hepatitis B vaccines: WHO position paper, July 2017 - Recommendations. Vaccine. 2019;37(2):223–225. doi: 10.1016/j.vaccine.2017.07.046.
    1. Bruce MG, Bruden D, Hurlburt D, Zanis C, Thompson G, Rea L, et al. Antibody levels and protection after hepatitis B vaccine: results of a 30-year follow-up study and response to a booster dose. J Infect Dis. 2016;214(1):16–22. doi: 10.1093/infdis/jiv748.
    1. Levy M, Koren G. Hepatitis B vaccine in pregnancy: maternal and fetal safety. Am J Perinatol. 1991;8(3):227–232. doi: 10.1055/s-2007-999384.
    1. Moro PL, Zheteyeva Y, Barash F, Lewis P, Cano M. Assessing the safety of hepatitis B vaccination during pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 1990-2016. Vaccine. 2018;36(1):50–54. doi: 10.1016/j.vaccine.2017.11.039.
    1. Sheffield JS, Hickman A, Tang J, Moss K, Kourosh A, Crawford NM, et al. Efficacy of an accelerated hepatitis B vaccination program during pregnancy. Obstet Gynecol. 2011;117(5):1130–1135. doi: 10.1097/AOG.0b013e3182148efe.
    1. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012;3:e00049. doi: 10.7554/eLife.00049.
    1. Giersch K, Allweiss L, Volz T, Dandrilz M, Luetgehetmann M. Serum HBV pgRNA as a clinical marker for cccDNA activity. J Hepatol. 2017;66(2):460–462. doi: 10.1016/j.jhep.2016.09.028.
    1. Lu FM, Wang J, Zhuang H. Potential clinical significance of HBV RNA virus-like particle. Zhonghua Gan Zang Bing Za Zhi. 2016;24(9):641–642. doi: 10.3760/cma.j.issn.1007-3418.2016.09.001.
    1. Lu FM, Dou XG, Zhang WH, Wang FS. Clinical significance of serum HBVRNA measurement in chronic hepatitis B patients. Zhonghua Gan Zang Bing Za Zhi. 2018;34(05):934–938. doi: 10.3969/j.issn.1001-5256.2018.05.005.
    1. McNaughton AL, D’Arienzo V, Ansari MA, Lumley SF, Littlejohn M, Revill P, et al. Insights from deep ssequencing of the HBV genome-unique, tiny, and misunderstood. Gastroenterology. 2019;156(2):384–399. doi: 10.1053/j.gastro.2018.07.058.
    1. Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: recent advances. J Gastroenterol Hepatol. 2011;26(Suppl 1):123–130. doi: 10.1111/j.1440-1746.2010.06541.x.
    1. Livingston SE, Simonetti JP, Bulkow LR, Homan CE, Snowball MM, Cagle HH, et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology. 2007;133(5):1452–1457. doi: 10.1053/j.gastro.2007.08.010.
    1. Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst. 2005;97(4):265–272. doi: 10.1093/jnci/dji043.
    1. Tang LSY, Covert E, Wilson E, Kottilil S. Chronic hepatitis B infection a review. JAMA. 2018;319(17):1802–1813. doi: 10.1001/jama.2018.3795.
    1. Indolfi G, Easterbrook P, Dusheiko G, Siberry G, Chang MH, Thorne C, et al. Hepatitis B virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019;4(6):466–476. doi: 10.1016/s2468-1253(19)30042-1.
    1. Nayagam S, Thursz M, Sicuri E, Conteh L, Wiktor S, Low-Beer D, et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis. 2016;16(12):1399–1408. doi: 10.1016/s1473-3099(16)30204-3.
    1. Liu J, Yao N, Chen T, Fu S, Wu Y, Feng Y, et al. Prevalence of mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis. J Hepatol. 2019;70(1):E123–E124. doi: 10.1016/s0618-8278(19)30217-8.
    1. Chinese Society of Infectious Diseases CMA Guidelines for prevention and treatment of mother-to-child transmission of hepatitis B virus in China. Zhonghua Gan Zang Bing Za Zhi. 2019;37(7) doi: 10.3760/cma.j.issn.1000-6680.2019.07.002.
    1. Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int. 2009;29:100–107. doi: 10.1111/j.1478-3231.2008.01941.x.
    1. Fanning GC, Zoulim F, Hou J, Bertoletti A. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov. 2019;18(11):827–844. doi: 10.1038/s41573-019-0037-0.
    1. Hui CK, Leung N, Yuen ST, Zhang HY, Leung KW, Lu L, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology. 2007;46(2):395–401. doi: 10.1002/hep.21724.
    1. Liaw YF. Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol. 2003;18(3):246–252. doi: 10.1046/j.1440-1746.2003.02976.x.
    1. Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med. 2004;116(12):829–834. doi: 10.1016/j.amjmed.2003.12.040.
    1. Chu CM, Liaw YF. Prevalence of and risk factors for hepatitis B viremia after spontaneous hepatitis B surface antigen seroclearance in hepatitis B carriers. Clin Infect Dis. 2012;54(1):88–90. doi: 10.1093/cid/cir755.
    1. Chu CM, Liaw YF. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther. 2010;15(2):133–143. doi: 10.3851/imp1497.
    1. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335–352. doi: 10.1016/j.jhep.2007.11.011.
    1. Chen YC, Chu CM, Liaw YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology. 2010;51(2):435–444. doi: 10.1002/hep.23348.
    1. Park BK, Park YN, Ahn SH, Lee KS, Chon CY, Moon YM, et al. Long-term outcome of chronic hepatitis B based on histological grade and stage. J Gastroenterol Hepatol. 2007;22(3):383–388. doi: 10.1111/j.1440-1746.2007.04857.x.
    1. Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol. 2007;46(1):45–52. doi: 10.1016/j.jhep.2006.08.021.
    1. Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis. 2006;26(2):142–152. doi: 10.1055/s-2006-939752.
    1. Chen YC, Chu CM, Yeh CT, Liaw YF. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int. 2007;1(1):267–273. doi: 10.1007/s12072-007-5001-0.
    1. Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35(6):1522–1527. doi: 10.1053/jhep.2002.33638.
    1. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med. 2001;135(9):759–768. doi: 10.7326/0003-4819-135-9-200111060-00006.
    1. Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology. 1995;21(1):77–82. doi: 10.1002/hep.1840210114.
    1. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis. 2003;23(1):47–58. doi: 10.1055/s-2003-37590.
    1. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology. 2013;57(2):441–450. doi: 10.1002/hep.26041.
    1. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012;142(5):1140–1149.e3. doi: 10.1053/j.gastro.2012.02.007.
    1. Zhang Z, Zhang JY, Wang LF, Wang FS. Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection. J Gastroenterol Hepatol. 2012;27(2):223–230. doi: 10.1111/j.1440-1746.2011.06940.x.
    1. Dandri M, Locarnini S. New insight in the pathobiology of hepatitis B virus infection. Gut. 2012;61:6–17. doi: 10.1136/gutjnl-2012-302056.
    1. Isogawa M, Tanaka Y. Immunobiology of hepatitis B virus infection. Hepatol Res. 2015;45(2):179–189. doi: 10.1111/hepr.12439.
    1. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol. 2001;19:65–91. doi: 10.1146/annurev.immunol.19.1.65.
    1. Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut. 2012;61(12):1754–1764. doi: 10.1136/gutjnl-2011-301073.
    1. Cornberg M, Wong VW, Locarnini S, Brunetto M, Janssen HLA, Chan HL. The role of quantitative hepatitis B surface antigen revisited. J Hepatol. 2017;66(2):398–411. doi: 10.1016/j.jhep.2016.08.009.
    1. Hou JL, Zhao W, Lee C, Hann HW, Peng CY, Tanwandee T, et al. Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries. Clin Gastroenterol Hepatol. 2020;18(2):457–467.e421. doi: 10.1016/j.cgh.2019.07.010.
    1. Kim JH, Sinn DH, Kang W, Gwak GY, Paik YH, Choi MS, et al. Low-Level Viremia and the Increased Risk of Hepatocellular Carcinoma in Patients Receiving Entecavir Treatment. Hepatology. 2017;66(2):335–343. doi: 10.1002/hep.28916.
    1. Wiegand J, Hasenclever D, Tillmann HL. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir Ther. 2008;13(2):211–220.
    1. Ni YH, Chang MH, Wang KJ, Hsu HY, Chen HL, Kao JH, et al. Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. Gastroenterology. 2004;127(6):1733–1738. doi: 10.1053/j.gastro.2004.09.048.
    1. Chu CJ, Hussain M, Lok ASF. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology. 2002;122(7):1756–1762. doi: 10.1053/gast.2002.33588.
    1. Watanabe K, Takahashi T, Takahashi S, Okoshi S, Ichida T, Aoyagi Y. Comparative study of genotype B and C hepatitis B virus-induced chronic hepatitis in relation to the basic core promoter and precore mutations. J Gastroenterol Hepatol. 2005;20(3):441–449. doi: 10.1111/j.1440-1746.2004.03572.x.
    1. Rajoriya N, Combet C, Zoulim F, Janssen HLA. How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach? J Hepatol. 2017;67(6):1281–1297.
    1. Jia W, Song LW, Fang YQ, Wu XF, Liu DY, Xu C, et al. Antibody to Hepatitis B Core Antigen Levels in the Natural History of Chronic Hepatitis B: A Prospective Observational Study. Medicine. 2014;93(29):e322. doi: 10.1097/md.0000000000000322.
    1. Song LW, Liu PG, Liu CJ, Zhang TY, Cheng XD, Wu HL, et al. Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection. Clin Microbiol Infect. 2015;21(2):197–203. doi: 10.1016/j.cmi.2014.10.002.
    1. Fan R, Sun J, Yuan Q, Xie Q, Bai X, Ning Q, et al. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. Gut. 2016;65(2):313–320. doi: 10.1136/gutjnl-2014-308546.
    1. Hou FQ, Song LW, Yuan Q, Fang LL, Ge SX, Zhang J, et al. Quantitative Hepatitis B Core Antibody Level Is a New Predictor for Treatment Response In HBeAg-positive Chronic Hepatitis B Patients Receiving Peginterferon. Theranostics. 2015;5(3):218–226. doi: 10.7150/thno.10636.
    1. Zhou J, Song L, Zhao H, Yan L, Ma A, Xie S, et al. Serum hepatitis B core antibody as a biomarker of hepatic inflammation in chronic hepatitis B patients with normal alanine aminotransferase. Sci Rep. 2017;7(1):2747. doi: 10.1038/s41598-017-03102-3.
    1. Wang J, Shen T, Huang X, Kumar GR, Chen X, Zeng Z, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol. 2016;65(4):700–710. doi: 10.1016/j.jhep.2016.05.029.
    1. Fan R, Zhou B, Xu M, Tan D, Niu J, Wang H, et al. Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucles(t)ide Analogue Therapy. Clin Gastroenterol Hepatol. 2020;18(3):719–727.e717. doi: 10.1016/j.cgh.2019.07.046.
    1. Wong DK, Seto WK, Cheung KS, Chong CK, Huang FY, Fung J, et al. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. Liver Int. 2017;37(7):995–1001. doi: 10.1111/liv.13346.
    1. Martinot-Peignoux M, Lapalus M, Maylin S, Boyer N, Castelnau C, Giuily N, et al. Baseline HBsAg and HBcrAg titres allow peginterferon-based ‘precision medicine’ in HBeAg-negative chronic hepatitis B patients. J Viral Hepat. 2016;23(11):905–911. doi: 10.1111/jvh.12565.
    1. Honda M, Shirasaki T, Terashima T, Kawaguchi K, Nakamura M, Oishi N, et al. Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma. J Infect Dis. 2016;213(7):1096–1106. doi: 10.1093/infdis/jiv572.
    1. Chuaypen N, Posuwan N, Payungporn S, Tanaka Y, Shinkai N, Poovorawan Y, et al. Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B. Liver Int. 2016;36(6):827–836. doi: 10.1111/liv.13046.
    1. Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol. 2017;112(1):18–35. doi: 10.1038/ajg.2016.517.
    1. Wang K, Lin W, Kuang Z, Fan R, Liang X, Peng J, et al. Longitudinal Change of Body Mass Index Is Associated With Alanine Aminotransferase Elevation After Complete Viral Suppression in Chronic Hepatitis B Patients. J Infect Dis. 2019;220(9):1469–1476. doi: 10.1093/infdis/jiz326.
    1. Amaddeo G, Cao Q, Ladeiro Y, Imbeaud S, Nault JC, Jaoui D, et al. Integration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas. Gut. 2015;64(5):820–829. doi: 10.1136/gutjnl-2013-306228.
    1. Seo SI, Kim HS, Kim WJ, Shin WG, Kim DJ, Kim KH, et al. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol. 2015;21(13):3928–3935. doi: 10.3748/wjg.v21.i13.3928.
    1. Wai CT, Cheng CL, Wee A, Dan YY, Chan E, Chua W, et al. Non-invasive models for predicting histology in patients with chronic hepatitis B. Liver Int. 2006;26(6):666–672. doi: 10.1111/j.1478-3231.2006.01287.x.
    1. Kim WR, Berge T, Asselah T, Flisiak R, Fung S, Gordon SC, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol. 2016;64(4):773–780. doi: 10.1016/j.jhep.2015.11.012.
    1. Dong XQ, Wu Z, Zhao H, Wang GQ, China Hep BRFA Evaluation and comparison of thirty noninvasive models for diagnosing liver fibrosis in chinese hepatitis B patients. J Viral Hepat. 2019;26(2):297–307. doi: 10.1111/jvh.13031.
    1. Sonneveld MJ, Brouwer WP, Chan HLY, Piratvisuth T, Jia JD, Zeuzem S, et al. Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study. Lancet Gastroenterol Hepatol. 2019;4(7):538–544. doi: 10.1016/s2468-1253(19)30087-1.
    1. Lemoine M, Shimakawa Y, Nayagam S, Khalil M, Suso P, Lloyd J, et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa. Gut. 2016;65(8):1369–1376. doi: 10.1136/gutjnl-2015-309260.
    1. Chen YP, Hu XM, Liang XE, Huang LW, Zhu YF, Hou JL. Stepwise application of fibrosis index based on four factors, red cell distribution width-platelet ratio, and aspartate aminotransferase-platelet ratio for compensated hepatitis B fibrosis detection. J Gastroenterol Hepatol. 2018;33(1):256–263. doi: 10.1111/jgh.13811.
    1. Yao M, Wang L, You H, Wang J, Liao H, Yang D, et al. Serum GP73 combined AST and GGT reflects moderate to severe liver inflammation in chronic hepatitis B. Clin Chim Acta. 2019;493:92–97. doi: 10.1016/j.cca.2019.02.019.
    1. Wang L, Liu T, Zhou J, You H, Jia J. Changes in serum chitinase 3-like 1 levels correlate with changes in liver fibrosis measured by two established quantitative methods in chronic hepatitis B patients following antiviral therapy. Hepatol Res. 2018;48(3):E283–E290. doi: 10.1111/hepr.12982.
    1. Yan L, Deng Y, Zhou J, Zhao H, Wang G, China Hep BRFA Serum YKL-40 as a biomarker for liver fibrosis in chronic hepatitis B patients with normal and mildly elevated ALT. Infection. 2018;46(3):385–393. doi: 10.1007/s15010-018-1136-2.
    1. European Association for the Study of the Liver, Asociacion Latinoamericana para el Estudio del Higado EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237–264. doi: 10.1016/j.jhep.2015.04.006.
    1. Chinese Foundation for Hepatitis Prevention and Control; Chinese Society of Infectious Disease and Chinese Society of Hepatology, Chinese Medical Association; Liver Disease Committee of Chinese Research Hospital Association Consensus on clinical application of transient elastography detecting liver fibrosis: a 2018 update. Zhonghua Gan Zang Bing Za Zhi. 2019;27(3):182–191. doi: 10.3760/cma.j.issn.1007-3418.2019.03.004.
    1. Chen YP, Liang XE, Dai L, Zhang Q, Peng J, Zhu YF, et al. Improving transient elastography performance for detecting hepatitis B cirrhosis. Dig Liver Dis. 2012;44(1):61–66. doi: 10.1016/j.dld.2011.08.004.
    1. Chen YP, Liang XE, Zhang Q, Peng J, Zhu YF, Wen WQ, et al. Larger biopsies evaluation of transient elastography for detecting advanced fibrosis in patients with compensated chronic hepatitis B. J Gastroenterol Hepatol. 2012;27(7):1219–1226. doi: 10.1111/j.1440-1746.2012.07122.x.
    1. Chan HL, Wong GL, Choi PC, Chan AW, Chim AM, Yiu KK, et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat. 2009;16(1):36–44. doi: 10.1111/j.1365-2893.2008.01037.x.
    1. Liang XE, Zhong C, Huang L, Yang S, Zhu Y, Chen Y, et al. Optimization of hepatitis B cirrhosis detection by stepwise application of transient elastography and routine biomarkers. J Gastroenterol Hepatol. 2017;32(2):459–465. doi: 10.1111/jgh.13475.
    1. Scott DR, Levy MT. Liver transient elastography (Fibroscan (R)): a place in the management algorithms of chronic viral hepatitis. Antivir Ther. 2010;15(1):1–11. doi: 10.3851/imp1474.
    1. Miao L, Yang WN, Dong XQ, Zhang ZQ, Xie SB, Zhang DZ, et al. Combined anluohuaxianwan and entecavir treatment significantly improve the improvement rate of liver fibrosis in patients with chronic hepatitis B virus infection. Zhonghua Gan Zang Bing Za Zhi. 2019;27(7):521–526. doi: 10.3760/cma.j.issn.1007-3418.2019.07.009.
    1. Jia J, Hou J, Ding H, Chen G, Xie Q, Wang Y, et al. Transient elastography compared to serum markers to predict liver fibrosis in a cohort of Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol. 2015;30(4):756–762. doi: 10.1111/jgh.12840.
    1. Fetzer DT, Rodgers SK, Seow JH, Dawkins AA, Joshi G, Gabriel H, et al. Ultrasound Evaluation in Patients at Risk for Hepatocellular Carcinoma. Radiol Clin North Am. 2019;57(3):563–583. doi: 10.1016/j.rcl.2019.01.004.
    1. Elsayes KM, Kielar AZ, Chernyak V, Morshid A, Furlan A, Masch WR, et al. LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance. J Hepatocell Carcinoma. 2019;6:49–69. doi: 10.2147/jhc.S186239.
    1. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1(5):431–435. doi: 10.1002/hep.1840010511.
    1. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 1991;13(3):372–374. doi: 10.1016/0168-8278(91)90084-o.
    1. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology. 1996;24(2):289–293. doi: 10.1002/hep.510240201.
    1. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22(6):696–699. doi: 10.1016/0168-8278(95)80226-6.
    1. Kim SU, Oh HJ, Wanless IR, Lee S, Han KH, Park YN. The Laennec staging system for histological sub-classification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosis. J Hepatol. 2012;57(3):556–563. doi: 10.1016/j.jhep.2012.04.029.
    1. Tailing W, Xia L, Yuanping Z, Jingwen H, Jing Z, Ningzhang L, et al. A Semiquantitative score system for assessment of hepatic inflammation and fibrosisi in chronic viral hepatits. Zhonghua Gan Zang Bin Za Zhi. 1998;6(4):195. doi: 10.3760/j.issn:1007-3418.1998.04.002.
    1. Xu S, Wang Y, Tai DCS, Wang S, Cheng CL, Peng Q, et al. qFibrosis: A fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients. J Hepatol. 2014;61(2):260–269. doi: 10.1016/j.jhep.2014.02.015.
    1. Sun Y, Zhou J, Wang L, Wu X, Chen Y, Piao H, et al. New Classification of Liver Biopsy Assessment for Fibrosis in Chronic Hepatitis B Patients Before and After Treatment. Hepatology. 2017;65(5):1438–1450. doi: 10.1002/hep.29009.
    1. Wong GL. Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend. Clin Mol Hepatol. 2018;24(2):108–113. doi: 10.3350/cmh.2017.0068.
    1. Martin P. Immune-Tolerant Hepatitis B: Maybe a Misnomer but Still Hard to Treat. Hepatology. 2019;69(6):2315–2317. doi: 10.1002/hep.30654.
    1. Maimone S, Caccamo G, Squadrito G, Alibrandi A, Saffioti F, Spinella R, et al. A combination of different diagnostic tools allows identification of inactive hepatitis B virus carriers at a single time point evaluation. Liver Int. 2017;37(3):362–368. doi: 10.1111/liv.13246.
    1. Liu J, Yang HI, Lee MH, Jen CL, Batrla-Utermann R, Lu SN, et al. Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression. Hepatology. 2016;64(2):381–389. doi: 10.1002/hep.28552.
    1. Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, Lok AS. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol. 2019;71(2):397–408. doi: 10.1016/j.jhep.2019.03.034.
    1. Wu X, Zhou J, Xie W, Ding H, Ou X, Chen G, et al. Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study. Infect Drug Resist. 2019;12:745–757. doi: 10.2147/idr.S185120.
    1. Suk KT, Baik SK, Yoon JH, Cheong JY, Paik YH, Lee CH, et al. Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol. 2012;18(1):1–21. doi: 10.3350/kjhep.2012.18.1.1.
    1. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217–231. doi: 10.1016/j.jhep.2005.10.013.
    1. D’Amico G, Morabito A, D’Amico M, Pasta L, Malizia G, Rebora P, et al. New concepts on the clinical course and stratification of compensated and decompensated cirrhosis. Hepatol Int. 2018;12(Suppl 1):34–43. doi: 10.1007/s12072-017-9808-z.
    1. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. doi: 10.1016/j.jhep.2017.03.021.
    1. Chinese Society of Hepatology CMA The guideline of prevention and treatment for chronic hepatitis B:a 2015 update. Zhonghua Gan Zang Bin Za Zhi. 2015;23(12):888–905. doi: 10.3760/cma.j.issn.1007-3418.2015.12.002.
    1. Mak LY, Seto WK, Fung J, Yuen MF. Novel developments of hepatitis B: treatment goals, agents and monitoring tools. Expert Rev Clin Pharmacol. 2019;12(2):109–120. doi: 10.1080/17512433.2019.1567327.
    1. Seto WK, Lo YR, Pawlotsky JM, Yuen MF. Chronic hepatitis B virus infection. Lancet. 2018;392(10161):2313–2324. doi: 10.1016/s0140-6736(18)31865-8.
    1. Ning Q, Wu D, Wang GQ, Ren H, Gao ZL, Hu P, et al. Roadmap to functional cure of chronic hepatitis B: An expert consensus. J Viral Hepat. 2019;26(10):1146–1155. doi: 10.1111/jvh.13126.
    1. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354(10):1001–1010. doi: 10.1056/NEJMoa051285.
    1. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354(10):1011–1020. doi: 10.1056/NEJMoa051287.
    1. Chang TT, Lai CL, Yoon SK, Lee SS, Coelho HSM, Carrilho FJ, et al. Entecavir Treatment for up to 5 Years in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B. Hepatology. 2010;51(2):422–430. doi: 10.1002/hep.23327.
    1. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, et al. Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B. Hepatology. 2010;52(3):886–893. doi: 10.1002/hep.23785.
    1. Xu Y, Zhang YG, Wang X, Qi WQ, Qin SY, Liu ZH, et al. Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis. World J Gastroenterol. 2015;21(25):7869–7876. doi: 10.3748/wjg.v21.i25.7869.
    1. Su TH, Hu TH, Chen CY, Huang YH, Chuang WL, Lin CC, et al. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int. 2016;36(12):1755–1764. doi: 10.1111/liv.13253.
    1. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-Term Monitoring Shows Hepatitis B Virus Resistance to Entecavir in Nucleoside-Naive Patients Is Rare Through 5 Years of Therapy. Hepatology. 2009;49(5):1503–1514. doi: 10.1002/hep.22841.
    1. Hou JL, Gao ZL, Xie Q, Zhang JM, Sheng JF, Cheng J, et al. Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial. J Viral Hepat. 2015;22(2):85–93. doi: 10.1111/jvh.12313.
    1. Liang X, Gao Z, Xie Q, Zhang J, Sheng J, Cheng J, et al. Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results. Hepatol Int. 2019;13(3):260–269. doi: 10.1007/s12072-019-09943-6.
    1. Liu Y, Corsa AC, Buti M, Cathcart AL, Flaherty JF, Miller MD, et al. No detectable resistance to tenofovir disoproxil fumarate in HBeAg plus and HBeAg- patients with chronic hepatitis B after 8years of treatment. J Viral Hepat. 2017;24(1):68–74. doi: 10.1111/jvh.12613.
    1. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381(9865):468–475. doi: 10.1016/s0140-6736(12)61425-1.
    1. Kim WR, Loomba R, Berg T, Schall REA, Yee LJ, Dinh PV, et al. Impact of Long-Term Tenofovir Disoproxil Fumarate on Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. Cancer. 2015;121(20):3631–3638. doi: 10.1002/cncr.29537.
    1. Lim YS, Byun KS, Yoo BC, Kwon SY, Kim YJ, An J, et al. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial. Gut. 2016;65(5):852–860. doi: 10.1136/gutjnl-2014-308353.
    1. Kim HJ, Cho JY, Kim YJ, Gwak GY, Paik YH, Choi MS, et al. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients. Korean J Intern Med. 2015;30(1):32–41. doi: 10.3904/kjim.2015.30.1.32.
    1. Suzuki F, Suzuki Y, Hosaka T, Sezaki H, Akuta N, Fujiyama S, et al. Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs. J Gastroenterol. 2017;52(5):641–651. doi: 10.1007/s00535-016-1270-5.
    1. Zhou J, Liu YY, Lian JS, Pan LF, Yang JL, Huang JR. Efficacy and Safety of Tenofovir Disoproxil Treatment for Chronic Hepatitis B Patients with Genotypic Resistance to Other Nucleoside Analogues: A Prospective Study. Chin Med J (Engl) 2017;130(8):914–919. doi: 10.4103/0366-6999.204107.
    1. Fasano M, Maggi P, Leone A, Volpe A, Fiore JR, Angarano G, et al. Long-term efficacy and safety of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate in virologically suppressed patients. Dig Liver Dis. 2017;49(5):530–534. doi: 10.1016/j.dld.2017.01.140.
    1. Rodriguez M, Manuel Pascasio J, Fraga E, Fuentes J, Prieto M, Sanchez-Antolin G, et al. Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study. World J Gastroenterol. 2017;23(41):7459–7469. doi: 10.3748/wjg.v23.i41.7459.
    1. Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, et al. Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study. J Hepatol. 2017;66(1):11–18. doi: 10.1016/j.jhep.2016.08.008.
    1. Lim YS, Lee YS, Gwak GY, Byun KS, Kim YJ, Choi J, et al. Monotherapy With Tenofovir Disoproxil Fumarate for Multiple Drug-Resistant Chronic Hepatitis B: 3-Year Trial. Hepatology. 2017;66(3):772–783. doi: 10.1002/hep.29187.
    1. Lim YS, Gwak GY, Choi J, Lee YS, Byun KS, Kim YJ, et al. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial. J Hepatol. 2019;71(1):35–44. doi: 10.1016/j.jhep.2019.02.021.
    1. Lee HW, Park JY, Lee JW, Yoon KT, Kim CW, Park H, et al. Long-term Efficacy of Tenofovir Disoproxil Fumarate Monotherapy for Multidrug-Resistant Chronic HBV infection. Clin Gastroenterol Hepatol. 2019;17(7):1348–1355.e2. doi: 10.1016/j.cgh.2018.10.037.
    1. Lim YS, Yoo BC, Byun KS, Kwon SY, Kim YJ, An J, et al. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. Gut. 2016;65(6):1042–1051. doi: 10.1136/gutjnl-2014-308435.
    1. Chan HLY, Fung S, Seto WK, Chuang WL, Chen CY, Kim H, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):185–195. doi: 10.1016/s2468-1253(16)30024-3.
    1. Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):196–206. doi: 10.1016/s2468-1253(16)30107-8.
    1. Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatology. 2018;68(4):672–681. doi: 10.1016/j.jhep.2017.11.039.
    1. Chinese Society of Hepatology CMA An expert consensus for the adjustment of treatment strategies in paints with chronic hepatitis B treated with non-first-line nucleos(t)ide analogues. Zhonghua Gan Zang Bin Za Zhi. 2019;27(5):343–346. doi: 10.3760/cma.j.issn.1007-3418.2019.05.004.
    1. Hsu CW, Su WW, Lee CM, Peng CY, Chuang WL, Kao JH, et al. Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B. J Formos Med Assoc. 2018;117(7):588–597. doi: 10.1016/j.jfma.2017.12.007.
    1. Fengqin H, Yalin Y, Lingying Z, Jia S, Guozhong G, Chen P, et al. Clinical effect and safety of pegylated interferon-α-2b injection (Y shape, 40 kD) in treatment of HBeAg-positive chronic hepatitis B patients. Zhonghua Gan Zang Bin Za Zhi. 2017;25(8):589–596. doi: 10.3760/cma.j.issn.1007-3418.2017.08.007.
    1. Zhang WH, Dou XG, Xie Q, Jiang JJ, Chen XY. Consensus on pegylated interferon alpha in treatment of chronic hepatitis B. Zhonghua Gan Zang Bin Za Zhi. 2017;25(9):678–686. doi: 10.3760/cma.j.issn.1007-3418.2017.09.007.
    1. Wu D, Wang P, Han M, Chen Y, Chen X, Xia Q, et al. Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study. Hepatol Int. 2019;13(5):573–586. doi: 10.1007/s12072-019-09956-1.
    1. Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial) J Hepatology. 2014;61(4):777–784. doi: 10.1016/j.jhep.2014.05.044.
    1. Han M, Jiang J, Hou J, Tan D, Sun Y, Zhao M, et al. Sustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon-alpha 2a: 1 year follow-up of the OSST study. Antivir Ther. 2016;21(4):337–344. doi: 10.3851/imp3019.
    1. Hu P, Shang J, Zhang W, Gong G, Li Y, Chen X, et al. HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study. J Clin Transl Hepatol. 2018;6(1):25–34. doi: 10.14218/jcth.2017.00072.
    1. Chan HLY, Chan FWS, Hui AJ, Li MKK, Chan KH, Wong GLH, et al. Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir - A prospective study. J Viral Hepat. 2019;26(1):126–135. doi: 10.1111/jvh.13000.
    1. Li SY, Li H, Xiong YL, Liu F, Peng ML, Zhang DZ, et al. Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: A five-year observational cohort study. J Viral Hepat. 2017;24:12–20. doi: 10.1111/jvh.12755.
    1. Ren P, Cao Z, Mo R, Liu Y, Chen L, Li Z, et al. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk. Expert Opin Biol Ther. 2018;18(10):1085–1094. doi: 10.1080/14712598.2018.1518423.
    1. Lampertico P, Messinger D, Cornberg M, Brunetto M, Petersen J, Kennedy P, et al. A genotype-specific baseline score predicts post-treatment response to peginterferon alfa-2a in hepatitis B e antigen-negative chronic hepatitis B. Ann Gastroenterol. 2018;31(6):712–721. doi: 10.20524/aog.2018.0300.
    1. Chan HL, Messinger D, Papatheodoridis GV, Cornberg M, Xie Q, Piratvisuth T, et al. A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B. Aliment Pharmacol Ther. 2018;48(5):547–555. doi: 10.1111/apt.14862.
    1. Chen H, Sun J, Zhou B, Xie Q, Liang X, Fan R, et al. Variants in STAT4 Associated With Cure of Chronic HBV Infection in HBeAg-positive Patients Treated With Pegylated Interferon-alpha. Clin Gastroenterol Hepatol. 2020;18(1):196–204.e198. doi: 10.1016/j.cgh.2019.04.044.
    1. Jiang YF, Ma J, He B, Li NP, Tang W, Gong GZ. The therapeutic effect of Anluohuaxian capsule combined with adefovir dipivoxil on patients with chronic hepatitis B and influence on hepatic histology. Zhonghua Gan Zang Bing Za Zhi. 2012;20(5):344–347. doi: 10.3760/cma.j.issn.1007-3418.2012.05.008.
    1. Lin W, Wei L, Yuhua G, Xi C, Fei P, Xueen L, et al. Effect of Anluohuaxianwan on the expression of matrix metalloproteinases and their inhibitors in rat liver with fibrosis. Zhonghua Gan Zang Bin Za Zhi. 2019;27(4):267–273. doi: 10.3760/cma.j.issn.l007-3418.2019.04.006.
    1. Liang M, Wanna Y, Xiaoqin D, Zhanqing Z, Shibin X, Dazhi Z, et al. Combined anluohuaxianwan and entecavir treatment significantly improve the improvement rate of liver fibrosis in patients with chronic hepatitis B virus infection. Zhonghua Gan Zang Bin Za Zhi. 2019;27(7):521–526. doi: 10.3760/cma.j.issn.1007-3418.2019.07.009.
    1. Yang NH, Yuan GS, Zhou YC, Liu JW, Huang HP, Hu CG, et al. Entecavir combined with Fufang Biejia Ruangan tablet in treatment of chronic hepatitis B patients with liver fibrosis: 96-week efficacy analyses. Nan Fang Yi Ke Da Xue Xue Bao. 2016;36(6):775–779.
    1. Ruihu Y, Qin L, Wei C. Efficacy and safety of Fuzhenghuayu capsule for treating liver fibrosis in patients with chronic hepatitis B: a meta-analysis. Zhonghua Gan Zang Bin Za Zhi. 2015;23(4):295–296. doi: 10.3760/cma.j.issn.1007-3418.2015.04.013.
    1. Chen J, Zhao SS, Liu XX, Huang ZB, Huang Y. Comparison of the Efficacy of Tenofovir Versus Tenofovir plus Entecavir in the Treatment of Chronic Hepatitis B in Patients With Poor Efficacy of Entecavir: A Systematic Review and Meta-analysis. Clin Ther. 2017;39(9):1870–1880. doi: 10.1016/j.clinthera.2017.07.015.
    1. Chaung KT, O’Brien C, Ha NB, Nguyen NH, Trinh HN, Nguyen MH. Alternative Therapies for Chronic Hepatitis B Patients With Partial Virological Response to Standard Entecavir Monotherapy. J Clin Gastroenterol. 2016;50(4):338–344. doi: 10.1097/mcg.0000000000000455.
    1. Bozza C, Cinausero M, Iacono D, Puglisi F. Hepatitis B and cancer: A practical guide for the oncologist. Crit Rev Oncol Hematol. 2016;98:137–146. doi: 10.1016/j.critrevonc.2015.10.017.
    1. Huang YH, Hsiao LT, Hong YC, Chiou TJ, Yu YB, Gau JP, et al. Randomized Controlled Trial of Entecavir Prophylaxis for Rituximab-Associated Hepatitis B Virus Reactivation in Patients With Lymphoma and Resolved Hepatitis B. J Clin Oncol. 2013;31(22):2765–2772. doi: 10.1200/jco.2012.48.5938.
    1. Liu CJ, Chen PJ, Chen DS, Kao JH. Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. Hepatol Int. 2013;7(2):316–326. doi: 10.1007/s12072-011-9279-6.
    1. Choi J, Lim YS. Characteristics, Prevention, and Management of Hepatitis B Virus (HBV) Reactivation in HBV-Infected Patients Who Require Immunosuppressive Therapy. J Infect Dis. 2017;216:S778–S784. doi: 10.1093/infdis/jix178.
    1. Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT. American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy. Gastroenterology. 2015;148(1):215–351. doi: 10.1053/j.gastro.2014.10.039.
    1. Sarmati L, Andreoni M, Antonelli G, Arcese W, Bruno R, Coppola N, et al. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper. Clin Microbiol Infect. 2017;23(12):935–940. doi: 10.1016/j.cmi.2017.06.023.
    1. Gentile G, Andreoni M, Antonelli G, Sarmati L. Screening, monitoring, prevention, prophylaxis and therapy for hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation: a systematic review. Clin Microbiol Infect. 2017;23(12):916–923. doi: 10.1016/j.cmi.2017.06.024.
    1. Zhang MY, Zhu GQ, Shi KQ, Zheng JN, Cheng Z, Zou ZL, et al. Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation. Oncotarget. 2016;7(21):30661–30677. doi: 10.18632/oncotarget.8907.
    1. Yang C, Qin B, Yuan Z, Chen L, Zhou HY. Meta-analysis of prophylactic entecavir or lamivudine against hepatitis B virus reactivation. Ann Hepatol. 2016;15(4):501–511.
    1. Liu WP, Xiao XB, Xue M, Wang GQ, Wang XP, Song YQ, et al. Prophylactic Use of Entecavir for Lymphoma Patients With Past Hepatitis B Virus Infection: A Randomized Controlled Trial. Clin Lymphoma Myeloma Leuk. 2019;19(2):103–108. doi: 10.1016/j.clml.2018.11.008.
    1. Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, et al. Hepatitis B Reactivation in Patients With Previous Hepatitis B Virus Exposure Undergoing Rituximab-Containing Chemotherapy for Lymphoma: A Prospective Study. J Clin Oncol. 2014;32(33):3736–3743. doi: 10.1200/jco.2014.56.7081.
    1. Kusumoto S, Tanaka Y, Suzuki R, Watanabe T, Nakata M, Takasaki H, et al. Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study. Clin Infect Dis. 2015;61(5):719–729. doi: 10.1093/cid/civ344.
    1. Buti M, Manzano ML, Morillas RM, Garcia-Retortillo M, Martin L, Prieto M, et al. Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study. Plos One. 2017;12(9):e0184550. doi: 10.1371/journal.pone.0184550.
    1. Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, et al. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood. 2019;133(2):137–146. doi: 10.1182/blood-2018-04-848044.
    1. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98. doi: 10.1007/s12072-015-9675-4.
    1. Liu WP, Wang XP, Zheng W, Ping LY, Zhang C, Wang GQ, et al. Hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy in patients with diffuse large B cell lymphoma. Leuk Lymphoma. 2016;57(6):1355–1362. doi: 10.3109/10428194.2015.1116121.
    1. Nakaya A, Fujita S, Satake A, Nakanishi T, Azuma Y, Tsubokura Y, et al. Delayed HBV reactivation in rituximab-containing chemotherapy: How long should we continue anti-virus prophylaxis or monitoring HBV-DNA? Leuk Res. 2016;50:46–49. doi: 10.1016/j.leukres.2016.09.014.
    1. Chinese Society of Hepatology CMA Consensus on clinical management of hepatitis B virus-infected women of childbearing age. Zhonghua Gan Zang Bin Za Zhi. 2018;26(3):204–208. doi: 10.3760/cma.j.issn.1007-3418.2018.03.009.
    1. Zou H, Chen Y, Duan Z, Zhang H, Pan C. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat. 2012;19(2):E18–E25. doi: 10.1111/j.1365-2893.2011.01492.x.
    1. Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y, et al. Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load. N Engl J Med. 2016;374(24):2324–2334. doi: 10.1056/NEJMoa1508660.
    1. Shang J, Wen Q, Wang CC, Liu K, Bai L, Tang H. Safety and efficacy of telbivudine for chronic hepatitis B during the entire pregnancy: Long-term follow-up. J Viral Hepat. 2017;24:43–48. doi: 10.1111/jvh.12785.
    1. Corbett AH, Kayira D, White NR, Davis NL, Kourtis AP, Chasela C, et al. Antiretroviral pharmacokinetics in mothers and breastfeeding infants from 6 to 24 weeks post-partum: results of the BAN Study. Antivir Ther. 2014;19(6):587–595. doi: 10.3851/imp2739.
    1. Benaboud S, Pruvost A, Coffie PA, Ekouévi DK, Urien S, Arrivé E, et al. Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d’Ivoire, in the ANRS 12109 TEmAA Study, Step 2. Antimicrob Agents Chemother. 2011;55(3):1315–1317. doi: 10.1128/AAC.00514-10.
    1. Chang CY, Aziz N, Poongkunran M, Javaid A, Trinh HN, Lau DT, et al. Serum Aminotransferase Flares in Pregnant and Postpartum Women With Current or Prior Treatment for Chronic Hepatitis B. J Clin Gastroenterol. 2018;52(3):255–261. doi: 10.1097/mcg.0000000000000822.
    1. Nguyen V, Tan PK, Greenup AJ, Glass A, Davison S, Samarasinghe D, et al. Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare. Aliment Pharmacol Ther. 2014;39(10):1225–1234. doi: 10.1111/apt.12726.
    1. ter Borg MJ, Leemans WF, de Man RA, Janssen HL. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat. 2008;15(1):37–41. doi: 10.1111/j.1365-2893.2007.00894.x.
    1. Jonas MM, Lok AS, McMahon BJ, Brown RS, Wong JB, Ahmed AT, et al. Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and meta-analysis. Hepatology. 2016;63(1):307–318. doi: 10.1002/hep.28278.
    1. Sokal EM, Paganelli M, Wirth S, Socha P, Vajro P, Lacaille F, et al. Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines Consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. J Hepatology. 2013;59(4):814–829. doi: 10.1016/j.jhep.2013.05.016.
    1. Wong GL, Seto WK, Wong VW, Yuen MF, Chan HL. Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B. Aliment Pharmacol Ther. 2018;47(6):730–737. doi: 10.1111/apt.14497.
    1. Komatsu H, Inui A, Fujisawa T. Pediatric hepatitis B treatment. Ann Transl Med. 2017;5(3):37. doi: 10.21037/atm.2016.11.52.
    1. Wirth S, Zhang H, Hardikar W, Schwarz KB, Sokal E, Yang W, et al. Efficacy and Safety of Peginterferon Alfa-2a (40KD) in Children With Chronic Hepatitis B: The PEG-B-ACTIVE Study. Hepatology. 2018;68(5):1681–1694. doi: 10.1002/hep.30050.
    1. Lampertico P, Chan HL, Janssen HL, Strasser SI, Schindler R, Berg T. Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients. Aliment Pharmacol Ther. 2016;44(1):16–34. doi: 10.1111/apt.13659.
    1. Han Y, Zeng A, Liao H, Liu Y, Chen Y, Ding H. The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: A systematic review and Meta-analysis. Int Immunopharmacol. 2017;42:168–175. doi: 10.1016/j.intimp.2016.11.022.
    1. Grossi G, Loglio A, Facchetti F, Borghi M, Soffredini R, Galmozzi E, et al. Tenofovir alafenamide as a rescue therapy in a patient with HBV-cirrhosis with a history of Fanconi syndrome and multidrug resistance. J Hepatol. 2018;68(1):195–198. doi: 10.1016/j.jhep.2017.08.020.
    1. Shah AS, Amarapurkar DN. Spectrum of hepatitis B and renal involvement. Liver Int. 2018;38(1):23–32. doi: 10.1111/liv.13498.
    1. Chinese Society of Infectious Disease CMA Guidelines for diagnosis and treatment of AIDS in China (2018 Edition) Zhonghua Xue Ye Xue Za Zhi. 2018;36(2):705–724. doi: 10.3760/cma.j.issn.1000-6680.2018.12.001.
    1. Li Y, Xie J, Han Y, Wang H, Zhu T, Wang N, et al. Lamivudine Monotherapy-Based cART Is Efficacious for HBV Treatment in HIV/HBV Coinfection When Baseline HBV DNA <20,000 IU/mL. J Acquir Immune Defic Syndr. 2016;72(1):39–45. doi: 10.1097/qai.0000000000000927.
    1. Li H, Zhang FJ, Lu HZ, Cai WP, Wu H, Sun YT, et al. Expert consensus on the management of patients with HIV infection and chronic kidney disease. Zhongguo Ai Zi Bin Xing Bin. 2017;23(6):578–583. doi: 10.13419/j.cnki.aids.2017.06.30.
    1. Yuen MF. Anti-viral therapy in hepatitis B virus reactivation with acute-on-chronic liver failure. Hepatol Int. 2015;9(3):373–377. doi: 10.1007/s12072-014-9569-x.
    1. Lisheng J, Yongguo L, Shu C, Yinghua L. Short-term and long-term efficacy of antiviral treatment of patients with HBV-associated acute-on-chronic liver failure. Zhonghua Xue Ye Xue Za Zhi. 2013;29(2):110–113. doi: 10.3969/j.issn.1001-5256.2013.02.009.
    1. Sun LJ, Yu JW, Zhao YH, Kang P, Li SC. Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure. J Gastroenterol Hepatol. 2010;25(3):583–590. doi: 10.1111/j.1440-1746.2009.06089.x.
    1. Zhang Y, Hu XY, Zhong S, Yang F, Zhou TY, Chen G, et al. Entecavir vs lamivudine therapy for naive patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. World J Gastroenterol. 2014;20(16):4745–4752. doi: 10.3748/wjg.v20.i16.4745.
    1. Huang KW, Tam KW, Luo JC, Kuan YC. Efficacy and Safety of Lamivudine Versus Entecavir for Treating Chronic Hepatitis B Virus-related Acute Exacerbation and Acute-on-Chronic Liver Failure A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2017;51(6):539–547. doi: 10.1097/mcg.0000000000000675.
    1. Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir Improves the Outcome in Patients with Spontaneous Reactivation of Hepatitis B Presenting as Acute-On-Chronic Liver Failure. Hepatology. 2011;53(3):774–780. doi: 10.1002/hep.24109.
    1. Zheng YS, Sun FL, Liu X. Comparative study on the therapeutic effects of telbivudine and entecavir on acute-on-chronic liver failure. J Clin Hepatol. 2011;27(6):641–642+646.
    1. Chinese Society of Infectious Disease CMA Guidelines for Diagnosis and Treatment of Liver Failure (2018 Edition) Zhonghua Xue Ye Xue Za Zhi. 2019;37(1):1–9. doi: 10.3760/cma.j.issn.1000-6680.2019.01.001.
    1. Sun P, Dong X, Cheng X, Hu Q, Zheng Q. Nucleot(s)ide Analogues for Hepatitis B Virus-Related Hepatocellular Carcinoma after Curative Treatment: A Systematic Review and Meta-Analysis. Plos One. 2014;9(7):e102761. doi: 10.1371/journal.pone.0102761.
    1. Yin J, Li N, Han Y, Xue J, Deng Y, Shi J, et al. Effect of Antiviral Treatment With Nucleotide/Nucleoside Analogs on Postoperative Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Two-Stage Longitudinal Clinical Study. J Clin Oncol. 2013;31(29):3647–3655. doi: 10.1200/jco.2012.48.5896.
    1. Huang G, Lau WY, Wang ZG, Pan ZY, Yuan SX, Shen F, et al. Antiviral Therapy Improves Postoperative Survival in Patients With Hepatocellular Carcinoma A Randomized Controlled Trial. Ann Surg. 2015;261(1):56–66. doi: 10.1097/sla.0000000000000858.
    1. Wong JS, Wong GL, Tsoi KK, Wong VW, Cheung SY, Chong CN, et al. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther. 2011;33(10):1104–1112. doi: 10.1111/j.1365-2036.2011.04634.x.
    1. Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, et al. Association Between Nucleoside Analogues and Risk of Hepatitis B Virus-Related Hepatocellular Carcinoma Recurrence Following Liver Resection. JAMA. 2012;308(18):1906–1913. doi: 10.1001/2012.jama.11975.
    1. Jang JW, Choi JY, Bae SH, Yoon SK, Chang UI, Kim CW, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology. 2006;43(2):233–240. doi: 10.1002/hep.21024.
    1. Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye QH, et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol. 2006;132(7):458–465. doi: 10.1007/s00432-006-0091-y.
    1. Lao XM, Luo G, Ye LT, Luo C, Shi M, Wang D, et al. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma. Liver Int. 2013;33(4):595–604. doi: 10.1111/liv.12112.
    1. Jang JW, Choi JY, Bae SH, Kim CW, Yoon SK, Cho SH, et al. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol. 2004;41(3):427–435. doi: 10.1016/j.jhep.2004.05.014.
    1. Peng JW, Lin GN, Xiao JJ, Jiang XM. Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization therapy. Asia Pac J Clin Oncol. 2012;8(4):356–361. doi: 10.1111/j.1743-7563.2012.01534.x.
    1. Kim JH, Park JW, Kim TH, Koh DW, Lee WJ, Kim CM. Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2007;69(3):813–819. doi: 10.1016/j.ijrobp.2007.04.005.
    1. Yeo W, Lam KC, Zee B, Chan PSK, Mo FKF, Ho WM, et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol. 2004;15(11):1661–1666. doi: 10.1093/annonc/mdh430.
    1. Maiwall R, Kumar M. Prevention and Treatment of Recurrent Hepatitis B after Liver Transplantation. J Clin Transl Hepatol. 2016;4(1):54–65. doi: 10.14218/jcth.2015.00041.
    1. Cholongitas E, Papatheodoridis GV. High Genetic Barrier Nucleos(t)ide Analogue(s) for Prophylaxis From Hepatitis B Virus Recurrence After Liver Transplantation: A Systematic Review. Am J Transplant. 2013;13(2):353–362. doi: 10.1111/j.1600-6143.2012.04315.x.
    1. Yi NJ, Choi JY, Suh KS, Cho JY, Baik M, Hong G, et al. Post-transplantation sequential entecavir monotherapy following 1-year combination therapy with hepatitis B immunoglobulin. J Gastroenterol. 2013;48(12):1401–1410. doi: 10.1007/s00535-013-0761-x.
    1. Teperman LW, Poordad F, Bzowej N, Martin P, Pungpapong S, Schiano T, et al. Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. Liver Transpl. 2013;19(6):594–601. doi: 10.1002/lt.23628.
    1. Chen G, Liu H, Hu ZQ, Bai JH, Liu QY, Zhao YP, et al. A new scheme with infusion of hepatitis B immunoglobulin combined with entecavir for prophylaxis of hepatitis B virus recurrence among liver transplant recipients. European J Gastroenterol Hepatol. 2015;27(8):901–906. doi: 10.1097/meg.0000000000000388.
    1. Wu J, Lu AD, Zhang LP, Zuo YX, Jia YP. Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia. Zhonghua Xue Ye Xue Za Zhi. 2019;40(1):52–57. doi: 10.3760/cma.j.issn.0253-2727.2019.01.010.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir